← All trials
NCT04801303
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 25, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Mar 17, 2021
- Last posted
- Sep 21, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaLead sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaSponsor investigator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaCollaborator
- Universitat de LleidaCollaborator
- Institut de Recerca Biomèdica de LleidaCollaborator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.